EBO2 (EBOO) for Autoimmune Conditions: Rheumatoid Arthritis, MS, Lupus and the Evidence

EBO2 (also called EBOO) is marketed to people with autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and lupus, usually on the premise that filtering and oxygenating the blood can calm an overactive immune system. This guide looks at that mechanism argument, what published studies of ozone and these specific conditions actually exist, how large and how controlled those studies are, and how they compare with a different blood-processing therapy that does have trial-based evidence for specific autoimmune conditions. For background on the procedure itself, see what EBO2 is; similar mechanism claims appear in marketing aimed at people with long COVID.

Why autoimmune patients are marketed EBO2

Autoimmune diseases involve the immune system mistakenly attacking the body’s own tissue, and conventional treatment often means long-term immunosuppressant or biologic medication with its own side effects, monitoring requirements, and considerable ongoing cost. Rheumatoid arthritis, multiple sclerosis, and lupus are three of the more common conditions in this category, each with its own pattern of flares and remissions that can make any treatment, effective or not, look like it is working if it happens to coincide with a natural improvement in symptoms that would have occurred anyway. That combination, a chronic condition and a demanding treatment regimen, makes patients a receptive audience for a therapy framed as working with the immune system rather than suppressing it. Clinic pages describe EBO2 as able to regulate immune responses and reduce inflammation in lupus, rheumatoid arthritis, and multiple sclerosis, and as helping manage autoimmune conditions generally by modulating the immune system [7][8]. These are broad claims covering multiple, biologically distinct diseases with the same short marketing language, a pattern this site’s clinic directory shows recurring across unrelated conditions, worth noticing on its own before looking at the underlying data. Ozone therapy is not FDA-approved to treat any autoimmune condition [9].

The mechanism hypothesis and how far the lab data go

The mechanism argument behind ozone therapy holds that a brief, controlled oxidative stress delivered to blood outside the body triggers a protective antioxidant and anti-inflammatory response when the blood is returned, potentially useful in diseases driven by chronic inflammation [1]. This argument comes from narrative reviews by long-time ozone-therapy proponents, synthesizing laboratory and small-patient biochemical data rather than presenting new controlled trials, and by the reviewing authors’ own account it explains a proposed biological pathway rather than demonstrating a clinical benefit in any specific disease [1]. The same review describes prolonged ozone inhalation as toxic while arguing that a single, precisely calibrated dose dissolved in blood outside the body acts differently, triggering biochemical responses in blood cells and the vessel lining that its authors, who are long-standing ozone-therapy proponents, describe as therapeutically useful in selected diseases [1]. A proposed mechanism is a reason to design a trial, not a substitute for one, and no such trial has tested this idea in an autoimmune population using EBO2 or measured whether it changes joint damage, relapse rate, organ involvement, or any other outcome a rheumatologist or neurologist would use to judge a treatment.

Condition by condition: what ozone studies exist

For rheumatoid arthritis, a PubMed search combining ozone autohemotherapy with rheumatoid arthritis returns a single result, and it is not actually a rheumatoid arthritis study: it is a single-patient case report describing a 69-year-old woman with Sjogren syndrome, a different autoimmune disease, who improved on standard measures of dryness and fatigue after six sessions of oxygen-ozone autohemotherapy [2]. The report comes from the Italian Society of Oxygen-Ozone Therapy, a professional body that promotes the treatment, describes one patient with no control group, and cannot show the ozone treatment caused the improvement rather than the natural waxing and waning common in Sjogren syndrome. That a search built around rheumatoid arthritis surfaces a single case study of an entirely different disease is itself a useful data point: it means a careful search of the published literature finds nothing at all, in any study design, testing EBO2 or ozone autohemotherapy specifically in rheumatoid arthritis patients.

For multiple sclerosis, several small studies from the same general research area have tested ozone autohemotherapy against laboratory immune markers rather than clinical disability. One example treated 20 people with relapsing-remitting MS with ozone twice weekly for six months and reported increases in regulatory T-cell markers associated with reduced inflammation, comparing patients only to their own pretreatment values with no placebo or sham-treatment group [3]. Changes in a circulating immune cell marker are not the same thing as a change in relapse rate, disability progression, or any outcome an MS patient would recognize as symptom improvement, and this study was not designed to measure either. The authors themselves frame the result as evidence that ozone autohemotherapy might regulate immune responses in a way worth studying further, a more modest claim than the treatment claims made on clinic marketing pages, and one that still stops short of showing any benefit a patient would feel. A companion paper from an overlapping set of authors reported changes in a second immune marker, Th17 cell frequency, in what appears to be the same small, uncontrolled cohort, which means the multiple sclerosis literature on ozone autohemotherapy is not several independent studies so much as one small research group publishing different biomarker slices of the same limited work [10].

For lupus, a PubMed search combining ozone therapy with lupus finds no studies of ozone as a treatment at all. Every result concerns a different subject entirely: ambient air pollution, ozone included, as a possible environmental trigger for lupus hospitalizations, an association a 2023 time-series study from China investigated using hospital admission data [4]. That is inhaled atmospheric ozone, a lung irritant the FDA also references when describing ozone as a toxic gas with no known useful medical application, not the medical-grade ozone gas mixed with blood outside the body in EBO2 [9]. The two exposures are not interchangeable, and this body of research neither supports nor undermines ozone therapy as a treatment; it simply means no one has published an ozone-therapy-for-lupus study of any kind, controlled or uncontrolled, for this guide to evaluate. A patient asking a clinic for the study behind an EBO2-for-lupus recommendation should expect the honest answer to be that none exists, not a citation to the air-pollution literature described above.

Interaction risks with immunosuppressants and biologics

None of the small studies above enrolled patients on biologic therapy or looked at interactions with immunosuppressants, so there is no published data on how ozone exposure interacts with these drugs or their infusion schedules. The 2021 ACR guideline reaffirms methotrexate as the first-line disease-modifying antirheumatic drug for rheumatoid arthritis and addresses the use of biologic and targeted synthetic DMARDs on top of it, including in patients with liver disease, heart failure, a history of serious infection, or other high-risk conditions, precisely the kind of medical complexity that makes an unstudied additional procedure a bigger decision than it might first appear [5]. Patients on methotrexate, a biologic, or another disease-modifying antirheumatic drug who are considering EBO2 should raise the timing of any blood-based procedure with the physician managing their infusions, given the total absence of data on how the two might interact and the fact that both involve the immune system and the bloodstream directly. A clinician managing a biologic infusion schedule is also the right person to weigh whether a repeated venous-access procedure adds any meaningful infection risk on top of a treatment that already suppresses part of the immune response.

Comparison with therapies that have evidence

Blood-processing procedures are not new to autoimmune treatment, and EBO2 is far from the first one proposed for this group of diseases. Therapeutic apheresis, most often plasma exchange, is a different procedure from EBO2 that removes and replaces plasma rather than filtering and ozonating whole blood, and it has an evidence-based grading system maintained by the American Society for Apheresis, now in its eighth edition and covering 84 disease fact sheets with 157 separately graded and categorized indications [6]. Each fact sheet places a specific disease and apheresis modality into a category from first-line to not recommended, based on a systematic review of trial evidence for that specific pairing, with conditions such as Guillain-Barre syndrome and myasthenia gravis in crisis graded as first-line indications [6]. No comparable grading exists for EBO2, or for ozone autohemotherapy, in any autoimmune condition, and no fact sheet in that guideline addresses either technique. The contrast is instructive: when a blood-processing treatment does have trial evidence for a specific autoimmune indication, medical societies say so explicitly, in a public, condition-by-condition grading system. EBO2 has no entry in that system.

Bottom line

Rheumatoid arthritis, multiple sclerosis, and lupus are marketed together as a single group of conditions EBO2 can help, using nearly identical language across clinic websites regardless of how differently these diseases actually behave, but the underlying evidence for each is different and uniformly weak: a single case report that is not actually about rheumatoid arthritis [2], a handful of small uncontrolled biomarker studies in multiple sclerosis [3][10], and no ozone-treatment studies of lupus at all [4]. None of it involves EBO2 specifically, and none of it used a control group capable of ruling out natural fluctuation in these relapsing, remitting diseases. Patients on immunosuppressants or biologics should discuss any additional blood-based procedure with the physician managing that treatment before scheduling one, and can reasonably ask why a graded, evidence-based blood-processing option like plasma exchange exists for some autoimmune conditions [6], spelled out fact sheet by fact sheet, while EBO2 has no such standing for any of them at all.